Antiviral Drugs for COVID-19 in Vaccinated Outpatients
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1671a ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19.
Abstract (Originalsprache)
Three products are currently available in the US for treatment of high-risk (see Table 1),1 nonhospitalized adults with mild to moderate COVID-19: oral ritonavir-boosted nirmatrelvir (Paxlovid), IV remdesivir (Veklury), and oral molnupiravir (Lagevrio). Remdesivir is FDA-approved for such use; nirmatrelvir/ritonavir and molnupiravir are available under an FDA Emergency Use Authorization. Because the pivotal clinical trials of these products for outpatient use were conducted in patients who were not vaccinated against COVID-19, some clinicians have questioned whether they can benefit vaccinated outpatients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). Antiviral Drugs for COVID-19 in Vaccinated Outpatients. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1671a
Vancouver
Antiviral Drugs for COVID-19 in Vaccinated Outpatients. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1671a
BibTeX
@article{euvimed2023,
title = {Antiviral Drugs for COVID-19 in Vaccinated Outpatients},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1671a}
}
EUVIMED